Corporate Statement

Mallinckrodt Pharmaceuticals is a multibillion dollar specialty pharmaceutical company focused on our mission: Listening for Needs. Delivering Solutions. We provide medicines to address unmet patient needs, stemming from 150 years of using our unique strengths, experience and expertise to help improve people’s lives. Discover how our rich history of innovation and patient-centered solutions has helped influence our vision for the future.

Investor Overview

News Releases

10 Apr '23
– Two scientific abstracts spanning clinical and health economic outcomes research will be presented at the 2023 NKF SCM, showcasing the breadth of Mallinckrodt's commitment to HRS patients with rapid reduction in kidney function [1]  – DUBLIN , April 10, 2023 /PRNewswire/ -- Mallinckrodt plc
21 Mar '23
– Findings from a retrospective analysis suggest that treatment with Acthar Gel is associated with significant reductions in corticosteroid use compared to other fourth-line alternatives for patients with advanced sarcoidosis 1  – DUBLIN  , March 21, 2023 /PRNewswire/ -- Mallinckrodt plc  (NYSE
09 Mar '23
– CELLEX ECP is now available for reimbursement in Japan for patients who are steroid-resistant or -intolerant and suffering from cGvHD – DUBLIN – March 9, 2023 –  Mallinckrodt plc , (NYSE American: MNK) (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today announced
go back to the top of the page